血清肿瘤标志物对非小细胞肺癌患者化疗疗效及生存的预测价值  

Prediction of Serum Tumor Markers Levels from Patients with Non-small-cell Lung Cancer and the Correlations with Efficacy of Chemotherapy and Survival Time

作　　者：崔媛媛[1,2] 俞婕[2] 骆雯[2] 张瑜[2] 

机构地区：[1]遵义医学院,贵州遵义563003 [2]贵州省人民医院肿瘤科,贵州贵阳550002

出　　处：《肿瘤基础与临床》2015年第6期516-519,共4页journal of basic and clinical oncology

基　　金：贵州省科学技术基金资助项目(编号:黔科合J字[2013]2181号)

摘　　要：目的探讨非小细胞肺癌(NSCLC)患者血清低氧诱导因子-1α(HIF-1α)、血管内皮生长因子(VEGF)、细胞角蛋白19的可溶性片段(CYFRA21-1)、糖分解烯醇(NSE)和癌胚抗原(CEA)表达水平与化疗疗效及生存时间的关系。方法入组NSCLC患者183例,动态监测化疗前、化疗后及随访期间血清HIF-1α、VEGF、CYFRA21-1、NSE和CEA的水平变化,将其与化疗疗效及生存时间进行相关性分析。结果化疗前HIF-1α、CYFRA21-1、NSE和CEA水平与NSCLC的临床分期、病理类型有关;HIF-1α、CYFRA21-1、NSE和CEA可较好预测化疗疗效,与化疗疗效呈负相关;HIF-1α和CYFRA21-1对腺癌、鳞癌生存具有良好的预测价值,CEA表达状况则与腺癌预后密切相关。结论动态联合监测HIF-1α、CYFRA21-1和CEA对预测NSCLC患者化疗疗效及生存时间具有重要意义。Objective To study the serum level changes of hypoxia-inducible factor-1α （HIF-1α）, vascular endothelial growth factor（ VEGF）, CYFRA21-1, neuron-specific enolase （ NSE ） and carcinoembryonic antigen （ CEA ） before and after chemotherapy in patients with non-small-cell lung cancer（NSCLC） , and to analyze their correlations with efficacy of chemotherapy and survival time. Methods The serum HIF-1α, VEGF, CYFRA21-1, NSE and CEA levels in the 183 patients with NSCLC were detected before chemotherapy, after chemotherapy and flow-up duration, and their correlations with efficacy of chemotherapy and survival time were analyzed. Results The serum HIF-1α, CYFRA21-1 ,NSE and CEA levels were related with clinical stage and pathological type; the serum HIF-1α, CY- FRA21-1, NSE and CEA levels were negatively related with efficacy of chemotherapy; the serum HIF-1α and CY- FRA21-1 levels were related with the survival time of patients with squamous cell carcinoma and adenocarcinoma, the serum CEA level was related with the survival time of patients with adenocarcinoma. Conclusion The serum level changes of HIF-1α, CYFRA21-1 and CEA can be used as the important indicators for evaluating the efficacy of chemotherapy and the survival time in the patients with NSCLC.

关 键 词：非小细胞肺癌 血清肿瘤标志物 化疗 生存时间 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]